肿瘤的免疫逃逸机制研究进展
The progresses of tumor escape mechanism
查看参考文献37篇
|
文摘
|
大量研究证实,肿瘤病人体内存在广泛的免疫逃避现象.目前所知的肿瘤逃逸机制很多,比如产生免疫抑制因子,改变表面抗原,通过Fas/Fasl反击机体的免疫系统而逃避机体的免疫监视,从而发生免疫逃逸.本文就肿瘤发生免疫逃逸机制的研究现状作一综述 |
|
其他语种文摘
|
The fact that the immune response to cancer is compromised has been convincingly demonstrated in cancer patients. There are many mechanisms of tumors escape, for example, the tumors can escape immunosurveillance through producing immunosuppressive factors, changing their surface antigens, and utilizing Fas/Fasl. In this article,we summarize the mechanisms by which how the escape happens |
|
来源
|
免疫学杂志
,2011,27(4):346-349,368 【核心库】
|
|
关键词
|
肿瘤
;
免疫逃逸
;
细胞因子
;
Fas/Fasl
|
|
地址
|
1.
泰州职业技术学院医学技术学院, 225300
2.
华中科技大学同济医学院八年制临床医学, 武汉, 430030
|
|
语种
|
中文 |
|
文献类型
|
综述型 |
|
ISSN
|
1000-8861 |
|
学科
|
基础医学 |
|
文献收藏号
|
CSCD:4165957
|
参考文献 共
37
共2页
|
|
1.
Ahmad M. Escape from immunotherapy:possible mechanisms that influence tumor regression/progression.
Cancer Immunol Immunother,2004,53(10):844-854
|
被引
6
次
|
|
|
|
|
2.
Yang L. Tumor.host immune interactions and dendritic cell dysfunction.
Adv Cancer Res,2004,92(1):13-27
|
被引
13
次
|
|
|
|
|
3.
Colombo MP. Regulatory T-cell inhibition versus depletion the fight choice in cancer immunotherapy.
Nat Rev Cancer,2007,7(11):880-887
|
被引
13
次
|
|
|
|
|
4.
Bissell DM. Transforming growth factor Band the liver.
Hepatology,2001,34(5):859-867
|
被引
31
次
|
|
|
|
|
5.
Feng XH. A kinase subdomain of TGFβtype I receptor determines the TGF-βintracellular signaling specificity.
EMBOJ,1997,16(233):3912-3923
|
被引
10
次
|
|
|
|
|
6.
张文岚. Smad蛋白家族与TGF--β信号传导.
深圳中西医结合杂志,2003,13(3):178-180
|
被引
5
次
|
|
|
|
|
7.
王启伟. Smad蛋白信号网络.
国外医学分子生物学分册,2003,25(4):206-209
|
被引
2
次
|
|
|
|
|
8.
Kretzschmar M. A mechanism of repression of TGFβ/Smad signaling by oncogenic Ras.
Gene&Development,1999,13(7):804-816
|
被引
20
次
|
|
|
|
|
9.
Xu XB. Obstruction of TGF-beta1 signal transduction can decrease the process of hepatocellular carcinoma in mice induced by CC14/ethanol.
Zhonghua Yi Xue Za Zhi,2004,84(13):1122-1125
|
被引
1
次
|
|
|
|
|
10.
Bacchetta R. Growth and expansion of human T regulatory typeⅠcells are independent from TCR activation but require exogenous cytokines.
Eur J Immunol,2002,32(8):2237-2245
|
被引
10
次
|
|
|
|
|
11.
Ahmadzadeh M. TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen--specific human memory CD8 T cells.
J Immunol,2005,174(9):5215-5223
|
被引
8
次
|
|
|
|
|
12.
Meadows SK. Human NK cell IFN-γproduction is regulated by endogenous TGFβ.
Int Immunopharmacol,2006,6(6):1020-1028
|
被引
1
次
|
|
|
|
|
13.
Frassanito MA. Deregulated cytokinenetwork and defective TH1 immune response in multiplemyeloma.
CtinEwp Immunol,2001,125(2):190-197
|
被引
4
次
|
|
|
|
|
14.
Sredni B. Ammonium trichloro(dioxoethylene-o,o')tellurate(AS101)sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop.
Cancer Res,2004,64(5):1843-1852
|
被引
9
次
|
|
|
|
|
15.
Kim ES. Transforming growth factor (TGF)-beta in conjunction with H-ras activation promotes malignant progression of MCF10A breast epithelial cells.
Cytokine,2005,29(2):84-91
|
被引
21
次
|
|
|
|
|
16.
. Salazar Onfray Interleukin 10:a cytokine used by tumors to escape immunosurveillance.
Med Oncol,1999,16(2):86-94
|
被引
1
次
|
|
|
|
|
17.
Dagvadorj J. Interleukin-10 inhibits tumor necrosis factor-αproduction in lipopolysaccharide-stimulated RAW 264.7 cells through reduced MyD88 expression.
Innate Immunity,2008,14(2):109-115
|
被引
2
次
|
|
|
|
|
18.
Allavena P. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages.
Eur J Immunol,1998,28(1):359-369
|
被引
21
次
|
|
|
|
|
19.
Dikov MM. Vascular endothelial growth factor effects on nuclear factor-kappaB activation in hematopoietic progenitor cells.
Cancer Res,2001,61(5):2015-2021
|
被引
4
次
|
|
|
|
|
20.
Price DJ. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells.
Cell Growth Differ,2001,12(3):129-135
|
被引
16
次
|
|
|
|
|
了解气象卫星更多信息，请访问